Video Experimental Relacionado
Updated: Jul 16, 2026
13:01
Anti-Nuclear Antibody Screening Using HEp-2 Cells
Published on: June 23, 2014
La poliarteritis nodosa también es una poliarteritis nodosa
1Division of Rheumatology, Johns Hopkins Vasculitis Center, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA. jstone@jhmi.edu
JAMA
|September 28, 2002
Resumen
La poliarteritis nodosa (PAN, por sus siglas en inglés), una vasculitis, puede ser difícil de diagnosticar. Este caso destaca el tratamiento exitoso con ciclofosfamida después de una década de diagnóstico erróneo de la enfermedad de Still en adultos.
Área de la Ciencia:
- Reumatología Reumatología.
- La vasculitis es una vasculitis.
- La terapia inmunosupresora es una terapia inmunosupresora.
Sus antecedentes:
- La poliarteritis nodosa (PAN) es una rara vasculitis sistémica.
- Los desafíos de diagnóstico en la vasculitis pueden llevar a un retraso en el tratamiento.
- Contexto histórico de PAN, haciendo referencia a la descripción inicial de Kussmaul y Maier.
Objetivo del estudio:
- Para presentar un caso complejo de poliarteritis nodosa de inicio en adultos (PAN).
- Para ilustrar los desafíos de diagnóstico en la vasculitis, diferenciando específicamente la PAN de la enfermedad de Still de inicio en adultos.
- Para resaltar la eficacia a largo plazo de la ciclofosfamida y la prednisona para lograr la remisión de la PAN refractaria.
Principales métodos:
- Informe de caso de un hombre de 30 años con un historial de síntomas de 12 años.
- Revisión de la presentación clínica que incluye fiebres, taquicardia, úlceras cutáneas y mononeuritis múltiple.
- Análisis de la respuesta al tratamiento con prednisona y posterior adición de ciclofosfamida.
Principales resultados:
- El paciente experimentó una década de diagnóstico erróneo, inicialmente tratado por la enfermedad de Still de inicio en adultos.
- La adición de ciclofosfamida a la terapia con prednisona dio lugar a la primera remisión sostenida.
- El paciente fue finalmente capaz de interrumpir todos los medicamentos inmunosupresores.
Conclusiones:
- Este caso subraya la importancia de considerar la PAN en pacientes con inflamación sistémica prolongada e inexplicable y características vasculares.
- La terapia inmunosupresora agresiva, incluida la ciclofosfamida, puede conducir a una remisión a largo plazo en casos difíciles de ANP.
- El manejo exitoso de la PAN puede potencialmente permitir la eventual interrupción de la inmunosupresión.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:25Endocarditis II: Clinical Features of Infective Endocarditis
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
01:22Pericarditis I: Introduction
Pericarditis is defined as the inflammation of the pericardium, the thin, sac-like membrane surrounding the heart. This condition can cause significant chest pain and other symptoms, often necessitating medical intervention. The pericardium has two layers: the inner visceral layer and the outer parietal layer, separated by a small amount of fluid that reduces friction during heartbeats.Types of PericarditisPericarditis can be classified into several types based on the duration and nature of the...
01:23Rheumatic Heart Disease I: Introduction
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
01:30Peripheral Artery Disease I: Introduction
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
01:24Nephrotic Syndrome I : Introduction
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...